Print
Email
Print Edition Stories
Aphios Corp. is due $2.4 million over two years to create a treatment for Alzheimer’s disease, courtesy of a Phase 2 SBIR grant the Woburn company received from The National Institute on Aging (NIA), part of the National Institutes of Health.
The biotechnology firm focuses on developing treatments for some cancers, infectious diseases and central nervous system disorders. It also works on a platform for drug development, nanotechnology drug delivery and pathogenic drug safety.
To treat Alzheimer’s, Aphios has developed APH-0703, a potent protein kinase C modulator. The company is working with Lousiana State University Health Science Center in Shreveport, La., to test APH-0703 with in vitro and in vivo efficacy, toxicity, and pharmacokinetic studies in mice with Alzheimer’s disease.
“An even more impressive finding is that an oral formulation of APH-0703 rapidly reversed cognitive deficits in animal models of AD,” J. Steven Alexander, LSU principal investigator, said in a statement, referring to APH-0703’s tests.
In June 2010, Aphios landed a $500,000 grant from U.S. Health and Human Services, administered by the NIH, as part of the American Recovery and Reinvestment Act.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
